UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended April 4, 2010

OR

TRANSITION REPORT PURSUANT TO SECTION 13

OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______

COMMISSION FILE NUMBER 1-3619

----

PFIZER INC.

(Exact name of registrant as specified in its charter)

DELAWARE

(State of Incorporation)

13-5315170

(I.R.S. Employer Identification No.)

235 East 42nd Street, New York, New York 10017

(Address of principal executive offices) (zip code)

(212) 733-2323

(Registrant s telephone number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.

YES x NO o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

YES x NO o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act (check one):

Large Accelerated filer x

Accelerated filer o

Non-accelerated filer o

Smaller reporting company o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

YES o NO x

At May 10, 2010, 8,066,133,809 shares of the issuer s voting common stock were outstanding.

FORM 10-Q

For the Quarter Ended

April 4, 2010

Table of Contents

PART I. FINANCIAL INFORMATION

Page

Item 1.

Financial Statements

Condensed Consolidated Statements of Income for the three months ended April 4, 2010, and March 29, 2009

Condensed Consolidated Balance Sheets as of April 4, 2010, and December 31, 2009

Condensed Consolidated Statements of Cash Flows for the three months ended April 4, 2010, and March 29, 2009

Notes to Condensed Consolidated Financial Statements

Review Report of Independent Registered Public Accounting Firm

20

Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

21

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

48

Item 4.

Controls and Procedures

48

PART II. OTHER INFORMATION

Item 1.

Legal Proceedings

48

Item 1A.

Risk Factors

51

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

51

Item 3.

Defaults Upon Senior Securities

52

Item 5.

Other Information

52

Item 6.

Exhibits

52

Signature

53

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(UNAUDITED)

Three Months Ended

(millions, except per common share data)

April 4,

2010

Mar. 29,

2009

Revenues

16,750

10,867

Costs and expenses:

Cost of sales(a)

4,306

1,408

Selling, informational and administrative expenses(a)

4,436

2,876

Research and development expenses(a)

2,226

1,705

Amortization of intangible assets

1,409

578

Acquisition-related in-process research and development charges

74

Restructuring charges and certain acquisition-related costs

706

554

Other (income)/deductions net

414

(57

Income from continuing operations before provision for taxes on income

3,179

3,803

Provision for taxes on income

1,146

1,074

Income from continuing operations

2,033

2,729

Discontinued operations net of tax

Net income before allocation to noncontrolling interests

2,035

2,730

Less: Net income attributable to noncontrolling interests

Net income attributable to Pfizer Inc.

2,026

2,729

Earnings per common share basic:

Income from continuing operations attributable to Pfizer Inc. common shareholders

0.25

0.41

Discontinued operations net of tax

Net income attributable to Pfizer Inc. common shareholders

0.25

0.41

Earnings per common share diluted:

Income from continuing operations attributable to Pfizer Inc. common shareholders

0.25

0.40

Discontinued operations net of tax

Net income attributable to Pfizer Inc. common shareholders

0.25

0.40

Weighted-average shares used to calculate earnings per common share:

Basic

8,061

6,723

Diluted

8,101

6,753

Cash dividends paid per common share

0.18

0.32

(a)

Exclusive of amortization of intangible assets, except as disclosed in Note 8B. Goodwill and Other Intangible Assets: Other Intangible Assets.

See accompanying Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

(millions of dollars)

April 4,

2010*

Dec. 31,

2009**

Assets

Cash and cash equivalents

1,759

1,978

Short-term investments

15,503

23,991

Accounts receivable, less allowance for doubtful accounts

13,611

14,645

Short-term loans

919

1,195

Inventories

10,132

12,403

Current deferred tax assets and other current assets

7,502

6,962

Assets held for sale

490

496

Total current assets

49,916

61,670

Long-term investments and loans

12,081

13,122

Property, plant and equipment, less accumulated depreciation

21,651

22,780

Goodwill

42,648

42,376

Identifiable intangible assets, less accumulated amortization

64,480

68,015

Noncurrent deferred tax assets and other noncurrent assets

4,337

4,986

Total assets

195,113

212,949

Liabilities and Shareholders Equity

Short-term borrowings, including current portion of long-term debt

7,769

5,469

Accounts payable

3,028

4,370

Dividends payable

1,454

Income taxes payable

765

10,107

Accrued compensation and related items

2,060

2,242

Current deferred tax liabilities and other current liabilities

12,301

13,583

Total current liabilities

25,924

37,225

Long-term debt

38,281

43,193

Pension benefit obligations

6,119

6,392

Postretirement benefit obligations

3,239

3,243

Noncurrent deferred tax liabilities

17,460

17,839

Other taxes payable

8,338

9,000

Other noncurrent liabilities

5,670

5,611

Total liabilities

105,031

122,503

Preferred stock

58

61

Common stock

443

443

Additional paid-in capital

70,456

70,497

Employee benefit trusts

(89

(333

Treasury stock

(21,697

(21,632

Retained earnings

42,429

40,426

Accumulated other comprehensive income/(loss)

(1,941

552

Total Pfizer Inc. shareholders equity

89,659

90,014

Equity attributable to noncontrolling interests

423

432

Total shareholders equity

90,082

90,446

Total liabilities and shareholders equity

195,113

212,949

Unaudited.

**

Condensed from audited financial statements.

See accompanying Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

Three Months Ended

(millions of dollars)

April 4,

2010

Mar. 29,

2009

Operating Activities:

Net income before allocation to noncontrolling interests

2,035

2,730

Adjustments to reconcile net income before allocation to noncontrolling interests to net

cash (used in)/provided by operating activities:

Depreciation and amortization

2,051

1,008

Share-based compensation expense

138

71

Acquisition-related in-process research and development charges

74

Deferred taxes from continuing operations

840

533

Other non-cash adjustments

319

(296

Changes in assets and liabilities, net of acquisitions and divestitures

(11,817

(899

Net cash (used in)/provided by operating activities

(6,360

3,147

Investing Activities:

Purchases of property, plant and equipment

(305

(253

Purchases of short-term investments

(2,178

(17,724

Proceeds from redemptions and sales of short-term investments

11,388

6,711

Purchases of long-term investments

(858

(3,442

Proceeds from redemptions and sales of long-term investments

1,127

889

Other investing activities

220

185

Net cash provided by/(used in) investing activities

9,394

(13,634

Financing Activities:

Increase in short-term borrowings

1,892

10,774

Principal payments on short-term borrowings

(3,663

(12,100

Proceeds from issuances of long-term debt

13,392

Principal payments on long-term debt

(9

(303

Cash dividends paid

(1,441

(2,133

Other financing activities

Net cash (used in)/provided by financing activities

(3,211

9,635

Effect of exchange-rate changes on cash and cash equivalents

(42

(23

Net decrease in cash and cash equivalents

(219

(875

Cash and cash equivalents at beginning of period

1,978

2,122

Cash and cash equivalents at end of period

1,759

1,247

Supplemental Cash Flow Information:

Cash paid during the period for:

Income taxes

10,547

454

Interest

792

84

See accompanying Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 1. Basis of Presentation

We prepared the condensed consolidated financial statements following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by accounting principles generally accepted in the United States of America (U.S. GAAP) can be condensed or omitted. Balance sheet amounts and operating results for subsidiaries operating outside the U.S. are as of and for the three-month periods ended February 28, 2010, and February 22, 2009.

On October 15, 2009, we completed our acquisition of Wyeth and, commencing from the acquisition date, our financial statements include the assets, liabilities, operating results and cash flows of Wyeth. As a result, legacy Wyeth operations are reflected in our results of operations and cash flows for the first quarter of 2010, but not for the first quarter of 2009.

Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.

We are responsible for the unaudited financial statements included in this document. The financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of our financial position and operating results.

The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2009.

Note 2. Adoption of New Accounting Policies

The provisions of the following new accounting standards were adopted as of January 1, 2010 and did not have a significant impact on our consolidated financial statements:

An amendment to the recognition and measurement guidance for the transfers of financial assets.

An amendment to the guidelines for determining the primary beneficiary in a variable interest entity.

Note 3. Acquisition of Wyeth

On October 15, 2009 (the acquisition date), we acquired all of the outstanding equity of Wyeth in a cash-and-stock transaction, valued at the acquisition date at approximately $68 billion. While Wyeth now is a wholly-owned subsidiary of Pfizer, the merger of local Pfizer and Wyeth entities may be pending or delayed in various international jurisdictions and integration in these jurisdictions is subject to completion of various local legal and regulatory obligations.

Recording of Assets Acquired and Liabilities Assumed

The following table summarizes the provisional amounts recognized for assets acquired and liabilities assumed as of the acquisition date as well as adjustments made in the first quarter of 2010 to the amounts initially recorded in 2009 (measurement period adjustments). The measurement period adjustments did not have a significant impact on our consolidated statements of income, balance sheets or cash flows in any period and, therefore, we have not retrospectively adjusted our financial statements. Certain estimated values are not yet finalized (see below) and are subject to change, which could be significant. We will finalize the amounts recognized as we obtain the information necessary to complete the analyses, but no later than one year from the acquisition date.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(millions of dollars)

Amounts Recognized

as of Acquisition Date

(as previously reported)

Measurement

Period

Adjustments

Amounts Recognized

as of Acquisition Date

(as adjusted)

Working capital, excluding inventories

16,342

16,342

Inventories

8,388

(167

8,221

Property, plant and equipment

10,054

(171

9,883

Identifiable intangible assets, excluding

in-process research and development (a)

37,595

(452

37,143

In-process research and development (a)

14,918

(956

13,962

Other noncurrent assets

2,394

2,394

Long-term debt

(11,187

(11,187

Benefit obligations

(3,211

(3,211

Net tax accounts

(24,773

761

(24,012

Other noncurrent liabilities

(1,908

(1,908

Total identifiable net assets

48,612

(985

47,627

Goodwill

19,954

985

20,939

Net assets acquired

68,566

68,566

Less: Amounts attributable to

noncontrolling interests

(330

(330

Total consideration transferred

68,236

68,236

(a)

The measurement period adjustments for Identifiable intangible assets reflect changes in the estimated fair value of certain acquired intangibles, principally in-process research and development assets, primarily to better reflect market participant assumptions about facts and circumstances existing as of the acquisition date. The measurement period adjustments did not result from intervening events subsequent to the acquisition date.

The recorded amounts are provisional and subject to change. Specifically, the following items are subject to change:

Amounts for intangibles and inventory, pending finalization of valuation efforts.

Amounts for legal contingencies, pending the finalization of our examination and evaluation of the portfolio of filed cases.

Amounts for income tax assets, receivables and liabilities pending the filing of Wyeth pre-acquisition tax returns, including all required disclosures and documentation, as well as the receipt of information from taxing authorities which may change certain estimates and assumptions used.

The allocation of goodwill among reporting units.

Note 4. Cost-Reduction Initiatives and Acquisition-Related Costs

We have incurred significant costs in connection with our cost-reduction initiatives (several programs initiated since 2005) and our acquisition of Wyeth on October 15, 2009.

Since the acquisition of Wyeth, our cost-reduction initiatives that were announced on January 26, 2009, but not completed as of December 31, 2009, have been incorporated into a comprehensive plan to integrate Wyeth s operations, generate cost savings and capture synergies across the combined company. We are focusing our efforts on achieving an appropriate cost structure for the combined company.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

We incurred the following costs in connection with all of our cost-reduction initiatives and the acquisition of Wyeth:

Three Months Ended

(millions of dollars)

April 4,

2010

Mar. 29,

2009

Transaction costs(a)

369

Integration costs(b)

208

28

Restructuring charges(c)

489

157

Restructuring charges and certain acquisition-related costs

706

554

Additional depreciation asset restructuring(d)

93

90

Implementation costs(e)

84

Total

799

728

(a)

Transaction costs represent external costs directly related to effecting the acquisition of Wyeth and primarily include expenditures for banking, legal, accounting and other similar services. Substantially all of the costs incurred in the first quarter of 2009 were fees related to a $22.5 billion bridge term loan credit agreement entered into with certain financial institutions on March 12, 2009 to partially fund our acquisition of Wyeth. The bridge term loan credit agreement was terminated in June 2009 as a result of our issuance of approximately $24.0 billion of senior unsecured notes in the first half of 2009.

(b)

Integration costs represent external, incremental costs directly related to integrating Wyeth and primarily include expenditures for consulting and systems integration.

(c)

Restructuring charges include the following:

Costs Incurred

Three Months Ended

Activity

Accrual

(millions of dollars)

April 4,

2010

Mar. 29,

2009

2005-2010

Through

April 4,

2010(1)

As of

April 4,

2010(2)

Employee termination costs

458

135

8,179

5,276

2,903

Asset impairments

18

1,458

1,458

Other

25

735

631

104

Total restructuring charges

489

157

10,372

7,365

3,007

(1)

Includes adjustments for foreign currency translation.

(2)

Included in Current deferred tax liabilities and other current liabilities ($2.0 billion) and Other noncurrent liabilities ($1.0 billion).

In the first quarter of 2010, the restructuring charges are related to the integration of Wyeth. From the beginning of our cost-reduction initiatives in 2005 through April 4, 2010, Employee termination costs represent the expected reduction of the workforce by approximately 45,400 employees, mainly in manufacturing, sales and research, of which approximately 28,100 employees have been terminated as of April 4, 2010. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination. Asset impairments primarily include charges to write down property, plant and equipment to fair value. Other primarily includes costs to exit certain assets and activities.

(d)

Additional depreciation asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions and are included in our condensed consolidated statements of income as follows:

Three Months Ended

(millions of dollars)

April 4,

2010

Mar. 29,

2009

Cost of sales

13

63

Selling, informational and administrative expenses

60

Research and development expenses

20

21

Total

93

90

(e)

Implementation costs in the first quarter of 2009 represent external, incremental costs directly related to implementing cost-reduction initiatives prior to our acquisition of Wyeth, and primarily include expenditures related to system and process standardization and the expansion of shared services. For the three months ended March 29, 2009, implementation costs are included in Cost of sales ($13 million), Selling, informational and administrative expenses ($40 million), Research and development expenses ($20 million) and Other (income)/deductions net ($11 million).

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 5. Financial Instruments

A. Selected Financial Assets and Liabilities

Information about certain of our financial assets and liabilities follows:

(millions of dollars)

April 4,

2010

Dec. 31,

2009

Selected financial assets measured at fair value on a recurring basis (a) :

Trading securities (b)

168

184

Available-for-sale debt securities(c)

23,787

32,338

Available-for-sale money market funds(d)

1,484

2,569

Available-for-sale equity securities, excluding money market funds(c)

243

281

Derivative financial instruments in receivable positions(e):

Foreign currency swaps

400

798

Interest rate swaps

315

276

Foreign currency forward-exchange contracts

284

502

Total

26,681

36,948

Other selected financial assets(f):

Short-term loans, carried at cost (g)

919

1,195

Held-to-maturity debt securities, carried at amortized cost(c)

642

812

Private equity securities, carried at cost or equity method (h)

858

811

Long-term loans, carried at cost(g)

782

784

Total

3,201

3,602

Total selected financial assets (i)

29,882

40,550

Financial liabilities measured at fair value on a recurring basis(a):

Derivative financial instruments in a liability position(j):

Foreign currency forward-exchange contracts

351

237

Foreign currency swaps

221

528

Interest rate swaps

73

25

Total

645

790

Other financial liabilities (k):

Short-term borrowings, carried at historical proceeds, as adjusted(f), (l)

7,769

5,469

Long-term debt, carried at historical proceeds, as adjusted(m), (n)

38,281

43,193

Total

46,050

48,662

Total selected financial liabilities

46,695

49,452

(a)

Fair values are determined based on valuation techniques categorized as follows: Level 1 means the use of quoted prices for identical instruments in active markets; Level 2 means the use of quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active or are directly or indirectly observable; Level 3 means the use of unobservable inputs. Virtually all of our financial assets and liabilities measured at fair value on a recurring basis use Level 2 inputs in the calculation of fair value, except that included in available-for-sale equity securities, excluding money market funds, are $93 million as of April 4, 2010 and $77 million as of December 31, 2009 of investments that use Level 1 inputs in the calculation of fair value. None of our financial assets and liabilities measured at fair value on a recurring basis are valued using Level 3 inputs as of April 4, 2010 or December 31, 2009.

(b)

Trading securities are held in trust for legacy Pharmacia severance benefits.

(c)

Gross unrealized gains and losses are not significant.

(d)

Includes approximately $1.2 billion of money market funds held in escrow to secure certain of Wyeth s payment obligations under its 1999 Nationwide Class Action Settlement Agreement, which relates to litigation against Wyeth concerning its former weight-loss products, Redux and Pondimin (see Note 5G. Financial Instruments: Guarantee).

(e)

Designated as hedging instruments, except for certain foreign currency contracts used as offsets; namely, foreign currency forward-exchange contracts with fair values of $150 million and foreign currency swaps with fair values of $36 million as of April 4, 2010; and foreign currency swaps with fair values of $106 million and foreign currency forward-exchange contracts with fair values of $100 million at December 31, 2009.

(f)

The differences between the estimated fair values and carrying values of our financial assets and liabilities not measured at fair value on a recurring basis were not significant as of April 4, 2010 or December 31, 2009.

(g)

Our short-term and long-term loans are due from companies with highly rated securities (Standard & Poor s (S&P) ratings of mostly AA or better).

(h)

Our private equity securities represent investments in the life sciences sector.

(i)

The decrease in selected financial assets is primarily due to the use of proceeds of short-term investments for tax payments made in the first quarter of 2010, associated with certain business decisions executed to finance the Wyeth acquisition.

(j)

Designated as hedging instruments, except for certain foreign currency contracts used as offsets; namely, foreign currency forward exchange contracts with fair values of $157 million and foreign currency swaps with fair values of $72 million as of April 4, 2010; and foreign currency forward-exchange contracts with fair values of $122 million and foreign currency swaps with fair values of $3 million as of December 31, 2009.

(k)

The carrying amounts may include adjustments for discount or premium amortization or for the effect of interest rate swaps designated as hedges.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(l)

Includes foreign currency borrowings with fair values of $2.3 billion at April 4, 2010 and $1.1 billion as of December 31, 2009, which are used as hedging instruments.

(m)

Includes foreign currency debt with fair value of $754 million as of April 4, 2010 and $2.1 billion as of December 31, 2009, which is used as a hedging instrument.

(n)

The fair value of our long-term debt is $41.7 billion as of April 4, 2010 and $46.2 billion as of December 31, 2009.

We use a market approach to determine the fair value of our financial assets and liabilities and apply the following methods and assumptions:

Trading equity securities quoted market prices.

Trading debt securities observable market interest rates.

Available-for-sale debt securities third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data and credit-adjusted interest rate curves.

Available-for-sale money market funds observable prices.

Available-for-sale equity securities, excluding money market funds third-party pricing services that principally use a composite of observable prices.

Derivative financial instruments (assets and liabilities) third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data. Where applicable, these models discount future cash flow amounts using market-based observable inputs including interest rate curves, foreign exchange rates, and forward and spot prices for currencies. The credit risk impact to our derivative financial instruments was not significant.

Held-to-maturity debt securities third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data and credit-adjusted interest rate curves.

Short-term and long-term loans third-party model that discounts future cash flows using current interest rates at which similar loans would be made to borrowers with similar credit ratings and for the same remaining maturities.

Private equity securities application of the implied volatility associated with an observable biotech index to the carrying amount of our portfolio and, to a lesser extent, performance multiples of comparable securities adjusted for company-specific information.

Short-term borrowings and long-term debt third-party matrix-pricing model that uses significant inputs derived from or collaborated by observable market data and our own credit rating.

In addition, we have long-term receivables where the determination of fair value uses discounted future cash flows, using current interest rates at which similar loans would be made to borrowers with similar credit ratings and for the same remaining maturities.

These selected financial assets and liabilities are presented in the condensed consolidated balance sheets as follows:

(millions of dollars)

April 4,

2010

Dec. 31,

2009

Assets

Cash and cash equivalents

380

666

Short-term investments

15,503

23,991

Short-term loans

919

1,195

Long-term investments and loans

12,081

13,122

Current deferred tax assets and other current assets(a)

313

526

Noncurrent deferred tax assets and other noncurrent assets(b)

686

1,050

Total

29,882

40,550

Liabilities

Short-term borrowings, including current portion of long-term debt

7,769

5,469

Current deferred tax liabilities and other current liabilities(c)

414

369

Long-term debt

38,281

43,193

Other noncurrent liabilities(d)

231

421

Total

46,695

49,452

(a)

As of April 4, 2010, derivative instruments at fair value include foreign currency forward-exchange contracts ($284 million) and foreign currency swaps ($29 million) and as of December 31, 2009, include foreign currency forward-exchange contracts ($503 million) and foreign currency swaps ($23 million).

(b)

As of April 4, 2010, derivative instruments at fair value include foreign currency swaps ($371 million) and interest rate swaps ($315 million) and as of December 31, 2009, include foreign currency swaps ($774 million) and interest rate swaps ($276 million).

10

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(c)

As of April 4, 2010, derivative instruments at fair value include foreign currency forward-exchange contracts ($351 million) and foreign currency swaps ($63 million) and as of December 31, 2009, include foreign currency forward-exchange contracts ($237 million) and foreign currency swaps ($132 million).

(d)

As of April 4, 2010, derivative instruments at fair value include foreign currency swaps ($158 million) and interest rate swaps ($73 million) and as of December 31, 2009, include foreign currency swaps ($396 million) and interest rate swaps ($25 million).

We regularly evaluate all of our financial assets for impairment. For investments in debt and equity securities, when a decline in fair value, if any, is determined to be other-than-temporary, an impairment charge is recorded, and a new cost basis in the investment is established. For loans, an impairment charge is recorded if it is probable that we will not be able to collect all amounts due according to the loan agreement. There were no significant impairments recognized in the first quarter of 2010 or the year ended December 31, 2009.

B. Investments in Debt and Equity Securities

The contractual maturities of the available-for-sale and held-to-maturity debt securities as of April 4, 2010, follow:

Years

(millions of dollars)

Within 1

Over 1

to 5

Total as of

April 4,

2010

Available-for-sale debt securities:

Western European and other government debt

9,157

2,576

11,733

Western European and other government agency debt

2,678

266

2,944

Corporate debt(a)

996

1,885

2,881

Federal Home Loan Mortgage Corporation and Federal National Mortgage

Association asset-backed securities

102

2,531

2,633

Reverse repurchase agreements(b)

1,263

1,263

U.S. government Federal Deposit Insurance Corporation guaranteed debt

1,101

1,101

Supranational debt

636

386

1,022